The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia

Blog Article

Terry Golombick, Terry DiamondDepartment of Endocrinology, St George Hospital, Kogarah, AustraliaAbstract: Plasma cell dyscrasias, most commonly associated with paraproteinemia, are a diverse group Insurance of diseases.Monoclonal gammopathy of undefined significance (MGUS) can precede multiple myeloma, a progressive neoplastic disease.MGUS occurs in association with a variety of other diseases and currently no treatment is recommended but rather “watchful waiting”.

Given that the size of the M-protein is a risk factor for disease progression, early intervention with the aim of reducing the paraprotein load would provide an innovative therapeutic tool.Preliminary results from our pilot study show a drop of between 5% and 30% serum paraprotein in patients taking curcumin compared with patients on placebo.Curcumin is a Figure Kits diferuloylmethane present in extracts of the rhizome of the Curcuma longa plant.

As a natural product, this has exciting potential in the treatment of plasma cell dyscrasias.Keywords: plasma cell dyscrasias, MGUS, myeloma, curcumin, paraproteinemia.